| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| WB Predicted band size | 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CRELD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CRELD2抗体的参考文献示例(注：以下内容为模拟示例，实际文献需通过学术数据库查询确认)：
---
1. **文献名称**：*CRELD2 regulates the unfolded protein response in mammalian cells*
**作者**：Smith A, et al.
**摘要**：该研究揭示了CRELD2蛋白在内质网应激反应中的作用，通过抗体检测发现其参与调控未折叠蛋白反应(UPR)通路，影响细胞应激适应性。
2. **文献名称**：*Expression and prognostic significance of CRELD2 in ovarian cancer*
**作者**：Zhang Y, et al.
**摘要**：利用CRELD2抗体进行免疫组化分析，发现其在卵巢癌组织中高表达，且与患者不良预后显著相关，提示其作为潜在肿瘤标志物的可能性。
3. **文献名称**：*Functional characterization of CRELD2 in cardiac development using antibody-based assays*
**作者**：Johnson R, et al.
**摘要**：通过Western blot和免疫荧光技术，研究CRELD2在小鼠心脏发育中的动态表达模式，表明其可能通过调控细胞间粘附参与心脏形态发生。
4. **文献名称**：*CRELD2 interacts with β-cell secretory pathways: Insights from co-immunoprecipitation studies*
**作者**：Lee S, et al.
**摘要**：使用CRELD2抗体进行共免疫沉淀实验，发现其与胰岛β细胞分泌通路蛋白相互作用，提示其在胰岛素分泌调控中的潜在作用。
---
建议通过PubMed、Google Scholar等平台，以“CRELD2 antibody”或“CRELD2 function”为关键词检索最新文献，并优先选择高影响力期刊的研究。
The CRELD2 (Cysteine-Rich with EGF-Like Domains 2) antibody is a tool used to study the CRELD2 protein, a member of the CRELD family implicated in cellular processes such as protein folding, endoplasmic reticulum (ER) stress response, and cell adhesion. CRELD2 is structurally characterized by multiple cysteine-rich motifs and epidermal growth factor (EGF)-like domains, which are thought to mediate protein-protein interactions. While its exact biological role remains under investigation, CRELD2 has been linked to ER quality control pathways, potentially assisting in the maturation or degradation of misfolded proteins. Dysregulation of CRELD2 has been associated with diseases, including certain cancers and congenital disorders, highlighting its potential clinical relevance.
Antibodies targeting CRELD2 are typically generated using immunogens derived from recombinant protein fragments or synthetic peptides corresponding to specific regions of the human or murine CRELD2 sequence. These antibodies are validated for applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Researchers use CRELD2 antibodies to explore its expression patterns, subcellular localization (e.g., ER residency), and interactions with chaperones like calnexin or BiP during stress conditions. Recent studies also investigate its role in tumor progression, where elevated CRELD2 levels may correlate with metastasis or drug resistance. Robust validation, including knockout cell line controls, is critical to ensure specificity due to potential cross-reactivity with other cysteine-rich proteins.
×
